QUOTED. Jan. 8, 2019. Johnathan Lancaster.
The UK's National Institute for Health and Care Excellence (NICE) added Myriad Genetics' EndoPredict test to its recommendations for breast-cancer treatment as new data show the long-term prognostic value of the EndoPredict test in guiding therapy for many of these patients. See what the firm's chief medical officer has to say about it here.
"Hopefully it will be a game-changing offering to the clinical market place and I'm highly optimistic that this is going to be incredibly well received and will be a source of improvements in outcomes for patients." – Johnathan Lancaster, chief medical officer, Myriad Genetics
Click here for a free trial of Medtech Insight.